Loading
NASDAQHealthcareBiotechnology
Latest quote
$487.61
−$2.63 · -0.54%
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Previous close
$487.61
−$2.63 · -0.54%
After-hours
$487.61
$0.00 · 0.00%
Sep 4, 7:30 PM ET
Regular session · ET · Market data may be delayed.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Day range
Current $487.61
52-week range
Current $487.61
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Buy
Favorable setup — positive multi-factor alignment
Valuation
91
Deep Value
Sentiment
66
Bullish
Risk
19
Low Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Day range
Current $487.61
52-week range
Current $487.61
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.18B USD | 2.88B USD | 2.33B USD | 1.94B USD | 1.69B USD |
| Cost of goods sold | 384.4M USD | 309.7M USD | 257.5M USD | 146.7M USD | 122.5M USD |
| Gross profit | 2.8B USD | 2.57B USD | 2.07B USD | 1.79B USD | 1.56B USD |
| Research and development | 550M USD | 481M USD | 408M USD | 322.9M USD | 540.1M USD |
| Selling, general, and administrative | 731.1M USD | 638.6M USD | 477.1M USD | 487M USD | 467M USD |
| Operating expenses | 1.28B USD | 1.19B USD | 885.1M USD | 809.9M USD | 1.01B USD |
| Interest income | 192M USD | 199.1M USD | 162.7M USD | 45.2M USD | 16.7M USD |
| Interest expense | 19.5M USD | 42.9M USD | 59.3M USD | 32.4M USD | 18.6M USD |
| Depreciation and amortization | 85.6M USD | 72.5M USD | 53.2M USD | 51.3M USD | 49.9M USD |
| Operating income | 1.52B USD | 1.38B USD | 1.18B USD | 979.7M USD | 555.9M USD |
| Net income | 1.33B USD | 1.2B USD | 984.8M USD | 727.3M USD | 475.8M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$643.75
32.02% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 23, 2009 | 2:1 | — | — |
Effective Sep 23, 2009
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Mid-Cap ETFIJH746.61M0.58%124.57B USD0.05%$75.85+0.13%
Vanguard Morningstar Total Stock Market ETFVTI699.87M0.03%2.3T USD0.03%$379.73-0.32%
Vanguard Morningstar Small-Cap ETFVB505.19M0.27%183.4B USD0.03%$300.01+0.05%
Vanguard Extended Market ETFVXF253.05M0.26%93.7B USD0.05%$242.66+0.14%
Vanguard Morningstar Small-Cap Value ETFVBR160.43M0.23%68.3B USD0.05%$247.11+0.08%
iShares Biotechnology ETFIBB156.44M1.48%10.72B USD0.44%$211.92-0.88%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY152.81M0.58%26.51B USD0.23%$691.52+0.13%
Vanguard Morningstar Small-Cap Growth ETFVBK146.03M0.33%43.8B USD0.05%$349.44+0.01%iShares Core S&P Mid-Cap ETFIJHVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap Value ETFVBRiShares Biotechnology ETFIBBState Street SPDR S&P MIDCAP 400 ETF TrustMDYVanguard Morningstar Small-Cap Growth ETFVBKAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
